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Recurrent episodes of life-threatening myoglobinuria in childhood are caused by inborn errors of glycogenolysis, mitochondrial fatty
acid beta-oxidation, and oxidative phosphorylation. Nonetheless, approximately half of the patients do not suffer from a defect in
any of these pathways. Using homozygosity mapping, we identiﬁed six deleterious mutations in the LPIN1 gene in patients who
presented at 2–7 years of age with recurrent, massive rhabdomyolysis. The LPIN1 gene encodes the muscle-speciﬁc phosphatidic acid
phosphatase, a key enzyme in triglyceride and membrane phospholipid biosynthesis. Of six individuals who developed statin-induced
myopathy, one was a carrier for Glu769Gly, a pathogenic mutation in the LPIN1 gene. Analysis of phospholipid content disclosed
accumulation of phosphatidic acid and lysophospholipids in muscle tissue of the more severe genotype. Mutations in the LPIN1
gene cause recurrent rhabdomyolysis in childhood, and a carrier state may predispose for statin-induced myopathy.Recurrent episodes of myoglobinuria are frequent features
of congenital metabolic myopathies. The differential diag-
nosis includes defects in glycogen breakdown, mitochon-
drial fatty acid beta oxidation, and oxidative phosphoryla-
tion.1 Diagnostic investigations including ischemic stress
tests, fatty acid oxidation studies in lymphocytes, and his-
tological, electron microscopic, and enzymatic determina-
tion of the mitochondrial respiratory chain in muscle fail
to detect the primary defect in approximately half of the
patients.2,3 In order to identify new etiologies, we used ho-
mozygosity mapping in patients who suffer from life-
threatening episodes of rhabdomyolysis and who originate
from small consanguineous families.
Three patients of Arab-Muslim origin (partly depicted in
Figure 1) were the subjects of this study. They were all born
at term, their birth and early motor and cognitive develop-
ment were uneventful. All suffered from recurrent episodes
of myoglobinuria, and these episodes were invariably pre-
cipitated by febrile illnesses and lasted 7–10 days. The ﬁrst
episode occurred around the second birthday in patients
2257 and 2120 and at 7 years in patient 2572. The present-
ing symptoms were generalized weakness, inability to
walk, myalgia, and dark urine. On examination, marked
sensitivity over the thighs and calf muscles was present,
but there was no swelling, localized warmth, or redness.
At presentation, the patients refused to lift the legs against
gravity but retracted the legs in response to painful stimuli,
muscle strength was markedly reduced, and the patellar
and Achilles reﬂexes could not be elicited bilaterally. Thestrength, tone, and reﬂexes of the upper limbs were usually
preserved. The central nervous system was typically spared
during the episodes; however, when ﬁrst admitted at age
18 months, patient 2120 was stuporous and had general-
ized muscle hypotonia; the EEG recording was abnormal
and showed slow background activity along with theta
and delta activity mainly above the occipital regions. Dur-
ing the episodes, plasma creatine kinase (CK) levels were
markedly elevated (peak levels 180,000-450,000 U, N <
150) with overt myoglobinuria. Lactate dehydrogenase
and aspartate aminotransferase were concomitantly ele-
vated (peak levels 24,540 u/liter and 12,620 u/liter, respec-
tively). The following tests gave normal results: CBC,
electrolytes, alkaline phosphatase, coagulation studies, al-
bumin and total proteins, cholesterol, triglycerides, urea,
creatinine, uric acid, blood gasses, plasma lactate, total
and free carnitine, blood acylcarnitine proﬁle, plasma
amino acids, beta-oxidation of labeled palmitate, CPT2 ac-
tivity in lymphocytes, and urinary organic acids. Normal
results were also obtained by inter-ictal electromyography,
brain CT scan, abdominal ultrasound, and echocardio-
gram. In a biopsy of patient 2120’s quadriceps two months
after an episode of rhabdomyolysis, the enzymatic activi-
ties of the ﬁve mitochondrial respiratory-chain complexes
and the pyruvate dehydrogenase complex were normal.
The muscle contained no excess fat or glycogen, and the
cytoarchitecture was preserved.
During the episodes, treatment with intravenous ﬂuids
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plasma creatinine and urinary output. Between episodes,
the patients enjoyed normal health. Their weight was at
the 25th–40th percentile, and their height was at the
10th–25th percentile. At the time of writing, a physical ex-
amination of the patients, aged 8–10 years, gave normal re-
sults, including normal fat distribution (Figure 2), muscle
strength, and deep-tendon reﬂexes. The patients partici-
pated in their age-appropriate physical activities, and
plasma CK levels were normal. Their intellectual abilities
were reportedly average, but patient 2120 at 9 years suf-
fered from mild learning disabilities.
All experiments involving DNA of the patients, their rel-
atives, healthy controls, and patients’ cells were approved
by the Hadassah Ethical Review Committee. The DNA of
the three patients was analyzed with GeneChip Human
Mapping 250K Nsp Array from Affymetrix, as previously
described.4 Patient 2572 was homozygous for nine regions
of more than 5 Mb, and patient 2257 was homozygous for
seven regions. Both patients were homozygous and shared
identical haplotype over 788 markers (rs2609168–
rs779379) on chromosome 2 at 6.14–13.00 Mb. Using
polymorphic microsatellite markers that spanned this re-
gion, we conﬁrmed homozygosity for the same allele in
the three patients and in none of their unaffected relatives
(Figure 1). Within this 6.85 Mb genomic region there were
46 ORFs. and one of them, LPIN1 [MIM 605518], was fur-
ther analyzed because of its predominant expression in
muscle. Sequence analysis of its 19 coding exons and the
ﬂanking intronic regions revealed a homozygous G-to-T
mutation at nucleotide 643; the result was that Glu215
was replaced by a termination codon (E215X). The LPIN1
mRNA:beta-actin mRNA ratio in the patients’ ﬁbroblasts
determined by real-time PCR was only 5.8% 5 4.7% of
the control. This mutation was not detected in 81 anony-
Figure 1. The Family Pedigree and the
Haplotypes along the Critical Region on
Chromosome 2
Patients’ symbols are filled. Numbered sym-
bols represent individuals whose DNA sam-
ples were available for analysis. The poly-
morphic microsatellite markers and their
chromosomal locations (in Mb) are given
in the upper left panel. Only siblings whose
DNA samples were available were included
in this figure.
Figure 2. Patient 2572, Age 10 Years
Note Normal Fat Distribution
mous individuals of Arab-Muslim ori-
gin or in 85 anonymous individuals
of Ashkenazi-Jewish origin.
The LPIN1 sequence analysis in an
additional 22 patients who suffered
from recurrent rhabdomyolysis re-
sulted in the identiﬁcation of ﬁve ad-
ditional mutations, all deleterious, in
four unrelated patients. The clinical
course of these patients was essen-
tially similar: They had normal early development and ep-
isodes of myoglobinuria precipitated by catabolic stress. All
developed normally between episodes. Their family his-
tory, clinical course, and genotypes are given in Table 1.
The following mutations were not detected in 75 anony-
mous individuals of French origin or in 75 anonymous in-
dividuals of Maghreb origin: Arg800X, c.297þ2T > C,
c.1259þ2T > C, and a ~2Kb genomic deletion that in-
cludes exons 18 and 19.
The LPIN1 gene encodes Lipin-1, a phosphatidic acid
phosphatase (EC 3.1.3.4) that consists of 890 amino acids
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Table 1. The Clinical, Biochemical, and Molecular Findings in the Index Patients and in an Additional Four Patients Who Were
Identified by Screening of a Cohort of 22 Unrelated Patients for Mutations in the LPIN1 Gene
Patient (Age at
Time of Writing)
Age at First Episode
(Number of Episodes)
Peak CK
Level (u/liter) Family History Muscle Findings
Genotype
(Mutation at
the DNA Level) Fibroblasts’ mRNA
2120, 2257, 2572
(8–10 years)
2–7 years (1–5) 180,000–450,000 consanguineous,
Arab-Muslim, seven
healthy siblings
normal lipid
content
E215X/ E215X
(c.643G > T)
6%
2714 (5 years) 3 years (2) 20,000 consanguineous,
Palestinian-Muslim,
three healthy siblings
normal lipid
content
R388X/ R388X
(c.1162C > T)
not available
L.R. (4 years) 15 months (6) 100,000 French,
nonconsanguineous
moderate lipid
accumulation
R800X (c.2398C > T) /
genomic deletion
of exon 18 and 19a
44%
D.A. (5 years) 27 months (3) 200,000 Mauritanien,
consanguineous
moderate lipid
accumulation
c.297þ2T > C/
c.297þ2T > Cb
74%
P.N. (8 years) 18 months (4) 80,000 French,
nonconsanguineous.
A brother died of
rhabdomyolysis at
16 months
not available c.1259þ2T > Cc/
genomic deletion
of exon 18 and 19a
Not available
a Patients L.R. and P.N. were heterozygous for an ~2Kb genomic deletion that included exon 18 and 19. The borders of this deletion were not determined.
b Patient D.A. was homozygous for a c.297þ2T > C mutation that was associated with the activation of a cryptic splice site in exon 1 and consequent
deletion of the last 106 bp of this exon.
c Patient P.N. was heterozygous for c.1259T > C mutation that resulted in skipping of exon 8.with two conserved domains, an N-terminal region that
spans the ﬁrst 114 residues, and the catalytic domain
LNS2 (Lipin/Ned1/Smp2) at amino acids 674–830. The
mutations identiﬁed in our patients, which create a stop
codon at residues 215, 388, and 800 or produce frame
shifts as a result of exons’ being skipped, are thus predicted
to result in truncated proteins lacking catalytic activity.
Nearly 20 years ago, mouse strains with spontaneous
mutations, Gly84Arg and a complex genomic rearrange-
ment in the murine ortholog of the LPIN1 gene, were de-
scribed. These mutants had a distinctive phenotype (ﬂd,
fatty liver dystrophy) characterized by dystrophic epididy-
mal fat pads with reduced plasma leptin levels and insulin
resistance, transient fatty liver, and severe hypertriglyceri-
demia resulting in a considerable death rate and peripheral
neuropathy.5,6 In contrast, transgenic mice overexpressing
the LPIN1 gene had a tendency to accelerate dietary-in-
duced obesity. In view of these complementary pheno-
types, it was suggested that subtle genetic variations in
LPIN1 expression levels might contribute to the range of
adiposity in human populations.7 The normal fat distribu-
tion and average weight percentiles in our patients exclude
such a role for the human LPIN1 gene. After the identiﬁca-
tion of the mutations in the patients, we reviewed their
ﬁles and noted normal plasma glucose, triglyceride, choles-
terol, LDL, and HDL levels even during times of severe
rhabdomyolysis. Cholesterol, LDL, HDL, and fasting glu-
cose levels in plasma samples of their three mothers,
aged 35-45, were also within the control range for age,
and there were no cases of diabetes in the extended family.
Thus, the clinical manifestations of LPIN1 mutations in
humans, unlike in mice, are conﬁned to skeletal muscle.The AmeriThis exclusive phenotypemight be explained by the nearly
ubiquitous expression of two other LPIN genes, LPIN2 and
LPIN3, encoding closely related proteins.8 LPIN1 expres-
sion is most prominent in skeletal muscle and adipose tis-
sue in both humans and mice. However, the human LPIN2
is similarly expressed in adipose tissue, which probably ac-
counts for the lack of lipodystrophy in our patients.
Phosphatidic acid phosphatase catalyzes the conversion
of phosphatidic acid (phosphatidate) to diacylglycerol
(DAG) in the triacylglycerol (TAG) synthesis pathway9 (Fig-
ure 3). Because of this prominent role in triglyceride me-
tabolism and the exclusivemuscle involvement in patients
with deleterious LPIN1 mutations, we hypothesized that
LPIN1mutations when combined with other factors atten-
uating lipid metabolism would result in overt myopathy.
To this end, we determined LPIN1 sequence in six adults
who developed signiﬁcant clinical myopathy with ele-
vated plasma CK levels while they were being treated
with statins for hypercholesterolemia. In two of the pa-
tients, we found nucleotide substitution in exons encod-
ing the catalytic site: One patient, of Arab origin, carried
a synonymous change, GGG to GGC at codon 750, which
is predicted by the ESEﬁnder program to abolish a binding
site of the SC35 splicing factor, and the other patient, of
Ashkenazi origin, carried an A-to-Gmutation at nucleotide
2306, resulting in replacement of the highly conserved
glutamic acid at codon 769 by glycine (E769G). An addi-
tional patient of Ashkenazi origin carried a C-to-T muta-
tion at nucleotide 1828, resulting in Pro610Ser, which
was not predicted to be pathogenic. Because the E769G
mutation was not present in the 14 individuals who did
not develop muscle symptoms while being treated withcan Journal of Human Genetics 83, 489–494, October 10, 2008 491
Figure 3. Triacylglycerol and Phospholipid Biosynthetic
Pathway
Abbreviations are as follows: AGPAT, 1-acyl-sn-glycero-3-phos-
phate acyltransferase; DAG, diacylglycerol; DGAT, diacylgly-
cerol acyltransferase; Glycerol-3-P, glycerol-3-phosphate;
LPC, lyso-phosphatidylcholine; LPE, lyso-phosphatidylethanol-
amine; PLA2, phospholipase A2; LPEAT, lysophosphatidyletha-
nolamine acyltransferase; LPCAT, lysophosphatidylcholine
acyltransferase; LIPIN, phosphatidic acid phosphatase;
MLCL, Monolyso-cardiolipin; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PI(4,5)P2, phosphatidylinositol
4,5-diphosphate; TAG, triacylglycerol; TAZ, 1-palmitoyl-2-
linoleoyl-phosphatidylcholine:monolysocardiolipin linoleoyl-
transferase.statins, we further studied the pathogenic nature of this
mutation by using a yeast strain harboring a deletion of
the gene encoding PAH1,10 the yeast homolog of human
LPIN2. This deletion mutant grew very slowly in glycerol
medium, a phenotype that was partially complemented
by expression of the wild-type human LPIN1 gene or the
LPIN1-P610S gene11 (Figure 4). In contrast, yeast PAH1 de-
letion mutants expressing human LPIN1-E769G hardly
supported growth on glycerol medium, indicating that
this mutation is of functional signiﬁcance. This mutation
was not detected in 85 anonymous individuals of Ashke-
nazi-Jewish origin or in 81 anonymous individuals of
Arab-Muslim origin.
Statins or 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors are widely used and are generally well
tolerated; however, their administration is associated
with myalgia in 1%–7% of the patients and with severe
myopathy in 0.5% of the patients.12,13 Although the
mechanism of this drug-induced myotoxicity is unknown,
a strong association was found between mild, reversible
statin-induced myopathy and a SNP within the SLCO1B1
gene.14 Moreover, a substantial proportion of the patients
who developed myopathy were found to carry a mutation
in genes responsible for one of the three common meta-bolic myopathies (Carnitine palmitoyl transferase 2 deﬁ-
ciency, McArdle disease, and myoadenylate deaminase de-
ﬁciency). The importance of screening for such risk factors
is underscored by the persistence of the muscle symptoms
in the majority of the patients despite cessation of the
lipid-lowering therapy.15 Given that an LPIN1 mutation
has been detected in an individual who developed severe
statin-induced myopathy, screening of a larger number of
statin-treated patients and controls is warranted.
Phosphatidic acid phosphatase is located at an intersec-
tion of phospholipid metabolism; DAG is the precursor
of the plasma membrane phospholipids phosphatidyl-
choline (PC) and phosphatidyl-ethanolamine (PE), and
phosphatidate is the precursor of cardiolipin, the major
phospholipid in mitochondrial membranes (Figure 3). Ab-
normal phospholipid content was found in the peripheral
nerves of the ﬂdmutant mice and was proposed to account
for the ataxia and tremor in these animals.16 To clarify the
effect of the deleterious mutations in the LPIN1 gene in
muscle, we determined the phospholipid content, as previ-
ously described17, in muscle tissues of patient 2120 and
patient D.A. while they were asymptomatic. The results
of this analysis, presented in Table 2, revealed normal
PE, PC, and cardiolipin content and slightly increasedFigure 4. Human LPIN1 but Not LPIN1- E769G Can Par-
tially Complement a Dpah1 Yeast Strain
Wild-type (WT-W303) and D pah1 strains harboring an empty
plasmid (Yep51) or plasmids encoding derivatives of the nor-
mal human LPIN1 (YEp-LPIN1), the mutant human LPIN1
(YEp-E769G or Yep-P610S) or the normal yeast PAH1
(pGH316) were grown overnight at 30C in glucose medium.
Cultures at a density of 4 3 107 cells/ml were serially diluted
at 10-fold intervals (numbered 1, 2, 3 and 4 for 101, 102, 103
and 104 dilutions, respectively) and 10 ml of each was spotted
onto plates containing 2% glucose or 2% glycerol. The cells
on glucose and glycerol medium were incubated at 30C for
3 and 7 days, respectively.
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Table 2. Phospholipid Content in Muscle
Phospholipid Level (nmol/mg Protein)
Muscle LPE PE LPC PC MLCL CL LPA PA
2120 0.45 2.7 5.9 27 3.0 3 1.2 0.5
D.A. 0.12 5.7 0.1 21 0.3 9 u.d 2.2
Shipment controls (n ¼ 3) 0.03 2.4 0.1 18 0.3 6 u.d 0.2
Disease controls (n ¼ 85)a n.d. n.d. 0.25 0.2 245 12 0.2 5 0.1 45 3 n.d. n.d.
Abbreviations: n.d., not determined; u.d., undetectable.
a Data from patients with mitochondrial myopathies collected for an unrelated research project. Hence, not all phospholipids were quantified.phosphatidate level. In patient 2120 but not in D.A., mark-
edly elevated amounts of lyso-phospholipids, including
lyso-phosphatidate, lyso-PE, lyso-PC, and the lyso-form
of cardiolipin, monolyso-cardiolipin (MLCL), were found.
The source of these lyso-phospholipids is a remodeling
process (Lands’ cycle) that is catalyzed by phospholipase
A2s and lysophospholipid acyltransferases. This rapid
turnover of the sn-2 acyl moiety of the phospholipids is es-
sential for membrane asymmetry and diversity.18–20 Alter-
ations of the lyso-phospholipid levels are expected to be
harmful to the plasma membrane and possibly to the mi-
tochondrial membranes. The importance of normal levels
of DAG, phosphatidate, and its metabolite, phosphatidyli-
nositol 4,5-diphosphate (Figure 3), is further underscored
by their role as potent lipid second messengers. Based on
our ﬁndings, we propose that a defect in phosphatidic
acid phosphatase results in lyso-phosphatidate accumula-
tion that competes with lyso-PE, lyso-PC, and MLCL for
their respective acyltransferases (LPEAT, LPCAT, and TAZ
in Figure 3) and that this leads to the accumulation of these
lysophospholipids. Further accumulation of lyso-phos-
pholipids during stress periods may result in acute rhabdo-
myolysis because these metabolites not only act as deter-
gents but may also perturb signal transduction. The
normal phospholipid content in the muscle of patient
D.A is probably the result of a splice-site mutation that al-
lows the production of a small but signiﬁcant amount of
normal transcript in muscle; this, in turn, could attenuate
the lyso-phosphatide accumulation in unstressful periods.
The lack of muscle tissue from additional patients cur-
rently precludes deﬁnitive conclusions.
In summary, deleterious mutations in LPIN1 are associ-
ated with recurrent episodes of rhabdomyolysis in early
childhood, possibly because of secondary lyso- phospho-
lipid accumulation. In view of the ﬁnding of a milder
LPIN1mutation in a patient who developed statin-induced
myopathy, screening of larger cohort of patients and con-
trols is warranted.
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